Share your videos with the world

Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved IMBRUVICA™ (ibrutinib) capsules, a first-in-class, once-daily, oral Bruton’s tyrosine kinase (BTK) inhibitor. This new approach to treating blood cancers works by blocking BTK, a protein that helps certain cancer cells live and grow.1 IMBRUVICA is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), or adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy. To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762540-janssen-ec-approval-imbruvica-mcl-cll/

The European Report on Development (ERD) 2013 seeks to contribute to the global reflection on the post-2015 development agenda. Based on an assessment of the Millennium Development Goals experience and on an analysis of the changing international context, and likely trends for the next 20-30 years, the ERD 2013 looks at key potential drivers of a post- 2015 global partnership, to tackle poverty in the poorest countries and promote structural transformation in an inclusive and sustainable manner. To view Multimedia News Release, go to http://www.multivu.com/mnr/60634-ec-post-2015-sustainable-future-plan

These materials are already known for their use in race cars and other lightweight vehicles: Carbon fiber or other high-tech plastics. Light, stable and economical. Now, especially in the context of energy consumption automakers are losing their fear of man made materials - formerly known as